GlassScriptPhysician profile
Ananth Selliyan
NPI 1215382536
$8,730.28
in general payments reported to CMS, 2019-2025
25 companies · $1,899 in 2025
The $1,899 reported for 2025 was more than what 88% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $427 · 2020: $620 · 2021: $1,025 · 2022: $1,258 · 2023: $1,874 · 2024: $1,627 · 2025: $1,899.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,401.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,400.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $4,041.01 | 2019-2025 | Clareon, Hydrus Microstent, Clareon Panoptix Pro |
| Abbvie INC. | $621.75 | 2022-2025 | Durysta, Lumigan, Alphagan P |
| Rxsight INC | $597.51 | 2023-2025 | Rxsight Contact Lens, Rxsight Injector Cartridge, Rxsight Injector Handpiece |
| Glaukos Corporation | $460.46 | 2023-2024 | Idose, Is3-Istent Infinitetrabecular Micro-Bypass System Model Is3, Istent Infinite Trabecular Micro-Bypass System Model Is3 |
| Bausch & Lomb Americas INC. | $418.19 | 2023-2025 | Miebo, Envista Envy Iol, Envista Mx60 Iol |
| Johnson & Johnson Surgical Vision, INC. | $394.49 | 2020-2025 | Tecnis Simplicity |
| Sight Sciences, INC. | $311.41 | 2021-2024 | Omni Surgical System |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $266.44 | 2021 | |
| Novartis Pharmaceuticals Corporation | $219.87 | 2021-2023 | |
| Allergan, INC. | $188.66 | 2020-2021 | |
| Sun Pharmaceutical Industries INC. | $178.88 | 2020-2025 | |
| Tarsus Pharmaceuticals, INC. | $155.87 | 2025 | Xdemvy |
| Ocular Therapeutix, INC. | $140.87 | 2022-2023 | Dextenza |
| Biotissue Holdings INC. | $129.17 | 2021-2024 | |
| Oyster Point Pharma, INC. | $112.00 | 2022-2025 | Tyrvaya |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec, INC. | $110.34 | 2021 | |
| Aerie Pharmaceuticals, INC. | $61.64 | 2020-2021 | |
| Amgen INC. | $54.82 | 2024 | Tepezza |
| Thea Pharma INC. | $54.51 | 2022-2024 | Iyuzeh |
| Horizon Therapeutics Plc | $53.56 | 2021-2023 | Tepezza |
| Harrow Eye, LLC | $50.20 | 2023-2024 | Iheezo |
| Kala Pharmaceuticals, INC. | $42.35 | 2020-2022 | |
| Johnson & Johnson Vision Care, INC. | $31.47 | 2021-2022 | |
| Ivantis, INC | $20.59 | 2020 | |
| Lkc Technologies, INC. | $14.22 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ananth Selliyan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.